Mirae Asset Global ETFs Holdings
NTLA icon

Mirae Asset Global ETFs Holdings’s Intellia Therapeutics NTLA Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.7M Buy
133,974
+9,481
+8% +$121K ﹤0.01% 1254
2025
Q4 		$1.12M Buy
124,493
+4,078
+3% +$56.1K ﹤0.01% 1456
2025
Q3 		$2.08M Sell
120,415
-9,091
-7% -$112K ﹤0.01% 1130
2025
Q2 		$1.22M Sell
129,506
-88,115
-40% -$724K ﹤0.01% 1350
2025
Q1 		$1.56M Sell
217,621
-9,634
-4% -$97.3K ﹤0.01% 1268
2024
Q4 		$2.65M Buy
227,255
+15,888
+8% +$248K 0.01% 984
2024
Q3 		$4.35M Sell
211,367
-23,448
-10% -$541K 0.01% 813
2024
Q2 		$5.26M Buy
+234,815
New +$5.59M 0.01% 730

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return